Ono Pharmaceuticals

Founded in 1717 and headquartered in Osaka, Japan, the company is recognized for its significant contributions in two primary sectors: Pharmaceuticals and Diagnostics. In the pharmaceutical domain, it has a strong focus on prescription drugs, while in the field of diagnostics, it accompanies its pharma offerings with innovative diagnostic tools and technologies. Among its most notable brands are Opdivo and Kyprolis. Opdivo, also known as Nivolumab, is a PD-1 immune checkpoint inhibitor, which has been a groundbreaking addition to cancer immunotherapy. Kyprolis, or Carfilzomib, is a proteasome inhibitor that is instrumental in the treatment of multiple myeloma and is developed in partnership with Amgen. Although it began in Japan and the home market continues to play a central role, the company's products and services have a robust presence in several key global markets. Noteworthy among these are the United States, China, and countries within the European Union. The company's international reach extends to various other markets worldwide, cementing its status as a leading entity in the healthcare and pharmaceutical industries. (Powered by AI)